Granblock® Core Ingredient Featured in European Journal of Pharmacology (October 2025) > VLOG

The core patented ingredient Granblock® of Medipeau Inc. has been featured in the European Journal of Pharmacology (IF 5.3, Elsevier, October 2025 issue) through a collaborative study with Professor Su Ryeon Seo and her research team at the College of Life Sciences, Kangwon National University.

This study identified that the natural compound Cynaroside, a key component of Granblock®,selectively inhibits Granzyme B (GrB) — an enzyme involved in skin inflammation and barrier damage —thereby scientifically verifying the potential of Granblock® to help reduce inflammation and support skin barrier recovery.

Granzyme B is known to be overactivated in chronic inflammatory skin conditions such as atopic dermatitis and psoriasis,
causing tissue damage and skin barrier breakdown.
According to the study, Cynaroside inhibited GrB activity, reduced inflammatory cell infiltration and cytokine secretion,
and helped protect essential skin structural proteins such as fibronectin and decorin, contributing to improved skin barrier integrity.

These findings demonstrate that Granblock® is an innovative, nature-derived ingredient designed to address skin inflammation beyond simple soothing or moisturizing effects.
Granblock® is formulated in Medipeau’s representative product line, Oleogel, which applies smoothly to the skin, absorbs without stickiness, and helps calm and moisturize irritated or sensitive skin.
Formulated with naturally derived ingredients, it is carefully designed for delicate and sensitive skin types.

Reference
Kim, S.S., Kim, N.K., Heo, Y.J., Han, S., Seo, S.R. (2025).
Preclinical study on cynaroside as a selective granzyme B inhibitor in the treatment of atopic dermatitis.
European Journal of Pharmacology, 1006, 178196.
DOI: https://doi.org/10.1016/j.ejphar.2025.178196